ArticleRadiation oncology journal2025
Efficacy and safety of high-dose hypofractionated palliative radiotherapy (40 Gy in 10 daily fractions) for non-small cell lung cancer.
Article in Radiation oncology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePalliative thoracic radiotherapy plays a crucial role in the management of patients with non-small cell lung cancer (NSCLC). Conventional dose-fractionation schemes often yield modest and short-lived tumor responses. This study aims to evaluate the efficacy and safety of a high-dose hypofractionated radiotherapy regimen of 40 Gy in 10 daily fractions in NSCLC. MATERIALS AND
methodsConsecutive NSCLC patients who underwent palliative thoracic radiotherapy using the 40 Gy in 10 daily fractions regimen between January 2017 and December 2022 were identified from institutional databases of two tertiary oncology centers. Treatment responses were assessed using the Response Evaluation Criteria in Solid Tumor criteria. Local tumor control rate was estimated using cumulative incidence function, considering death as a competing event. The rates of radiation pneumonitis and esophagitis were assessed.
resultsSixty-two eligible patients were included. Median age was 72.6 years, with 52 patients (83.4%) having Eastern Cooperative Oncology Group performance status of ≥2. Radiotherapy was given to 33 patients (53%) with locally advanced primary NSCLC and 29 patients (47%) with oligopersistent or oligoprogressive NSCLC. Fifty-three tumors (85.4%) were considered unsuitable for stereotactic radiotherapy by location or size. With a median follow-up of 4.1 years, the overall response rate was 69.3%. Local control rates at 1 and 3 years were 96.7% and 76.9%, respectively. Grade 1-2 radiation pneumonitis and esophagitis occurred in 46.7% and 8.1% of patients. One case of grade 3 esophagitis was observed.
conclusionThe 40 Gy in 10 daily fractions regimen demonstrates high local tumor control rate and a favorable safety profile, representing an effective and safe palliative option for NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.